U.S. Biotech Stock News

Labcorp recently announced the nationwide availability of the Lumipulse pTau-217/Beta Amyloid 42 Ratio, the first FDA-cleared blood-based in-vitro diagnostic test to aid in the diagnosis of Alzheimer's disease in appropriate patients, developed by Fujirebio Diagnostics Inc. This launch offers a more accessible and less invasive alternative to traditional Alzheimer's diagnostics, coinciding with new clinical guidelines that endorse blood-based biomarkers for evaluating cognitive...

NYSE:SMWB 1 Year Share Price vs Fair Value Explore Similarweb's Fair Values from the Community and select yours Key...

In recent days, concerns have grown among Check Point Software Technologies Ltd. shareholders regarding the company's elevated price-to-earnings (P/E) ratio of 23.6x, which stands out compared to many US companies. This focus has intensified as analysts project slower-than-market-average earnings growth over the next three years, prompting questions about whether the company's valuation is sustainable. We'll explore how worries about the high P/E ratio and slower earnings growth influence...

If you’ve been watching Enphase Energy stock lately, you know just how lively this ticker can get. Whether you’re thinking of doubling down or nervously eyeing your portfolio, ENPH has kept investors on their toes. Over the past month, the stock dipped about 10%, with a 70% drop over the last year, making even long-term holders take a second look. Yet, short-term momentum is showing a bit more pep, climbing around 4% over the last week. All this volatility often reflects big changes in how...

If you’ve been tracking Chipotle Mexican Grill (CMG), you might have noticed the stock's slide this year and wondered if it signals a deeper shift ahead. There has been no major catalyst behind the move, but the consistent downturn could raise flags for investors deciding whether to stay invested for potential gains or consider trimming their positions. Although earnings have continued to grow at a steady rate, the market’s reaction suggests something may be changing in how future...

PNC Financial Services Group recently appointed Amy Wierenga as its new chief risk officer, with her tenure beginning on September 8, succeeding Kieran Fallon who returns to the legal department in a senior advisory role. This leadership change underscores the importance of experienced risk oversight at PNC, especially as the company navigates a complex regulatory and operational landscape. We'll explore how Wierenga's appointment may shape PNC's risk management approach and the broader...

Certainly, here is the revised article with em dashes removed and formatting improved: If you have been watching the action in DraftKings lately, you have likely found yourself asking, "Is now the time to buy in, hold tight, or lock in some gains?" It is a fair question, especially after the stock’s impressive climb. Over just the last quarter alone, DraftKings shares have soared more than 30%, and they remain up nearly 26% for the year. Over the longer term, the company has rewarded...

If you have been eyeing Samsara's stock lately, you are not alone. This is one ticker that tends to spark debates, whether you are thinking about jumping in or just weighing your options. Over the past year, Samsara has seen some dramatic shifts. Though the stock price has dropped about 20% in the last twelve months and is down nearly 25% year-to-date, that does not always tell the full story about the company's potential or how the market views its risk. Curious observers will also notice a...

DRDGOLD Limited reported its full-year results for the period ended June 30, 2025, with sales rising to ZAR 7.88 billion and net income reaching ZAR 2.24 billion, up from ZAR 6.24 billion and ZAR 1.33 billion respectively, in the previous year. The company’s prior guidance suggested substantial year-on-year growth in earnings per share and headline earnings per share, which highlights improved profitability momentum. We’ll explore how the stronger earnings guidance supports DRDGOLD’s...

It’s not every day that Verizon Communications (VZ) quietly adds over 6% in a single month, so investors are understandably looking at the stock and wondering what might be behind its recent run. No dramatic headlines are grabbing market attention, yet this steady climb is enough to raise eyebrows. This is especially notable with the wireless giant’s year-to-date performance sitting at an impressive 12%. With market sentiment changing and risk perceptions evolving, these moves suggest that...

Qfin Holdings recently reported strong second quarter earnings with revenue of CNY 5.22 billion and net income of CNY 1.73 billion, completed a buyback of 7.1 million shares for US$277 million, raised its first half 2025 dividend to US$0.38 per share, and issued new earnings guidance for the third quarter of 2025. This combination of higher earnings, a substantial share repurchase, and an increased dividend reflects the company’s operational momentum and management’s confidence despite...

NYSE:CAH 1 Year Share Price vs Fair Value Explore Cardinal Health's Fair Values from the Community and select yours...

If you have been watching First Citizens BancShares (FCNC.A), the company’s latest move deserves your attention. The bank just wrapped up a major part of its buyback program, purchasing 486,324 shares for over $916 million in four months. This brings total repurchases under the current plan to more than 1.6 million shares, or 11.5% of the company’s outstanding stock. This signals management’s strong conviction in the business and its long-term prospects. For investors, buybacks like these...

Thinking about whether to buy, hold, or sell Pfizer stock? You are not alone, especially after the recent movement in the share price. Over the last three months, Pfizer is up more than 10%, bouncing back from a rocky year in which it’s still down about 6% overall. This pick-up is catching the market’s attention and leading some investors to wonder if the tide is finally turning for the pharmaceutical giant or if this is just a temporary respite. A few recent headlines have contributed to...

If you're trying to figure out whether now is the right time to buy, hold, or sell Yum! Brands stock, you are definitely not alone. Even the savviest investors find themselves pausing here, glancing at the numbers, and wondering if this is a case of steady momentum or if something bigger is brewing beneath the surface. Over the past year, Yum! Brands has returned just over 10% for shareholders, with a nice 11.8% gain year-to-date. In addition, the longer-term gains are hard to ignore; the...

Deciding what to do with Cisco Systems (CSCO) right now feels like one of those classic investor crossroads. The company just released its fourth quarter and full-year earnings, revealing steady year-over-year growth in both revenue and net income. In addition, management provided guidance for fiscal 2026 that points to even more gains ahead, suggesting momentum may not fade anytime soon. For investors watching from the sidelines or holding on for the long haul, these consecutive positive...

If you are eyeing Emerson Electric stock and wondering if now is the time to buy, you are not alone. Investors have taken notice of this industrial stalwart after a series of price swings. EMR is up an impressive 28% over the last year and a remarkable 107% over the past five years. Even if you have only been watching the stock for a few months, you have probably seen it rise more than 11% in the past quarter despite a recent pullback of 8% over the last month. Much of this movement has been...

BMO recently introduced the BMO Escape Credit Card in partnership with Mastercard, targeting travelers with benefits such as up to US$240 in annual hotel credits, Priority Pass lounge membership, rebates on Global Entry, TSA PreCheck or NEXUS fees, and no foreign transaction charges. This collaboration enhances Mastercard’s reach in the travel rewards market, offering cardholders accelerated points on travel spend and broadening its competitive positioning among travel-focused consumer...

On August 12, 2025, Aflac announced it increased its share repurchase program authorization by 100 million shares, raising the total to 380 million shares. This substantial buyback expansion may reflect management's confidence in Aflac's ongoing financial strength and capital management approach. We'll explore how the expanded buyback authorization could influence Aflac's investment narrative, especially regarding future earnings per share growth. Trump's oil boom is here - pipelines are...

Occidental Petroleum Corporation recently provided updated third quarter 2025 production guidance, expecting output to reach 1.42 million to 1.46 million barrels of oil equivalent per day across all main operating areas. This signals continued operational momentum and a broad-based production increase, suggesting progress in efficiency and capacity expansion across Occidental's core assets. We'll examine how the higher production guidance adds weight to Occidental's investment narrative...

In August 2025, Novo Nordisk ended its partnership with Hims & Hers Health over the promotion and sale of compounded GLP-1 weight-loss drugs and instead announced a new collaboration with GoodRx to offer FDA-approved Ozempic and Wegovy at a competitive monthly price. This move not only heightened legal and regulatory risks for Hims & Hers but also intensified competitive pressure in the telehealth weight loss market. GoodRx’s partnership with Novo Nordisk highlights how innovative...

Thinking about what to do with PACCAR stock right now? You are not alone. Plenty of investors are eyeing this industrial leader and wondering whether all that long-term growth is already baked into the price, or if there is more upside waiting. The journey of PACCAR’s share price in the last year has been anything but boring. Despite some dips, the stock is still up nearly 6.5% over the past year and has more than doubled over the last five years—a seriously strong showing for a company in...

If you have been monitoring Kanzhun (NasdaqGS:BZ), this week’s events may give you pause to reconsider your next move. The company announced improved results for both revenue and net income in the second quarter and first half of 2025, and then added momentum by declaring its first ever annual dividend. Adding to this, the company introduced an upsized $250 million buyback plan, making it clear that management aims to signal financial strength and a commitment to shareholder returns. These...

Sabine Royalty Trust reported its earnings for the second quarter and first half of 2025, posting second-quarter revenue of US$18.7 million and net income of US$17.79 million, both lower than the previous year. An interesting point is that basic earnings per share from continuing operations also declined year over year, reflecting the overall drop in financial performance. We’ll explore how the declines in both revenue and earnings per share influence Sabine Royalty Trust’s investment...